Acquired Clotting Factor Deficits During Treatment with Asparaginase in an Institutional Cohort

Abstract

Vasiliki Papadopoulou, Giulia Schiavini Service and Laboratory of Hematology, Department of Oncology, Lausanne University Hospital, Lausanne, SwitzerlandCorrespondence: Vasiliki Papadopoulou, Lausanne University Hospital, Rue du Bugnon 46, Lausanne, 1011, Switzerland, Tel [phone], Email [email protected]: We invariably see prolongation of activated partial thromboplastin time in patients treated with asparaginase in our clinical practice, but have noted that, contrary to hypofibrinogenemia and low antithrombin, clotting times’ prolongation by asparaginase is largely unreported in the literature and guidelines and is not widely known to clinicians. We report on aPTT prolongations in a small cohort of patients, and on their origin, as investigated by measurements of clotting factors, fibrinogen, and D-dimers before and after asparaginase administration. We observed significant reductions in FIX and FXI (median post-treatment values of 27 IU/dl and 52 IU/dl, respectively), confirming one previous observation. A decrease in FXII was less pronounced but contributed to the prolonged aPTTs (FXII has no effect on in vivo haemostasis). The factor deficits are not due to consumption, as evidenced by unchanged D-dimer levels, and are, therefore, probably caused by disturbed factor synthesis. Our observations and insights contribute to elucidation of the profile of clotting assays during asparaginase treatment, and thus, to optimally monitor for undesirable events or steer situations of therapeutic anticoagulation without the risk of suboptimal or excessive anticoagulation.Keywords: asparaginase, clotting assays, acute lymphoblastic leukemia, NK-cell lymphoma, bleeding, thrombosis

Keywords

• asparaginase
• clotting assays
• acute lymphoblastic leukemia
• nk-cell lymphoma
• bleeding
• thrombosis